ArticleJournal of breast cancer2026
Challenges in Identifying Sentinel Lymph Nodes in Early Breast Cancer Patients: Should We Opt for Standard Axillary Lymph Node Dissection?
Article in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeAssessing the metastatic status of axillary lymph nodes is critical in breast cancer to determine disease progression and guide treatment. Axillary lymph node dissection (ALND) is performed when sentinel lymph nodes (SLNs) are undetectable; however, this can lead to overtreatment and complications. This study investigated whether limited axillary lymph node dissection (L-ALND) provides outcomes comparable to those of standard axillary lymph node dissection (S-ALND) in patients with early stage breast cancer.
methodsMedical records of 2,461 patients were reviewed, focusing on 304 cases with undetectable SLNs. After excluding those with three or more metastatic nodes, 217 patients with early-stage disease were analyzed. They were classified into L-ALND (≤ 9 nodes removed) and S-ALND (≥ 10 nodes removed) groups.
resultsThe L-ALND group had a lower local recurrence rate (1.6% vs. 3.4%) and fewer complications than the S-ALND group. Similarly, the five- and ten-year recurrence-free survival rates were higher in the L-ALND group than in the S-ALND group (95.0% vs. 89.1% and 94.2% vs. 49.5%). Factors affecting recurrence included the ALND type (S-ALND vs. L-ALND), type of operation, and tumor subtype. The incidence of lymphedema was also lower in the L-ALND group than in the S-ALND group (4.8% vs. 10.3%).
conclusionL-ALND offers outcomes comparable to S-ALND in early-stage breast cancer, reducing complications without compromising oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.